Clinical trial · Interventional
Safety and Efficiency of γδ T Cell Against Lung Cancer
γδ T Cell Immunotherapy for Treatment of Lung Cancer
NCT03183232CI-TRIAL-00045911completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this study, effects of γδT cells on human Lung Cancer in combination with tumor reducing surgery, for example, cryosurgery going to be investigated
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cryosurgery or IRE surgery | Procedure | — | UNRESOLVED |
| γδ T cell | Biological | — | UNRESOLVED |
| γδ T cells/ A Cryosurgery or IRE | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group A
- description
- In this group, the patients will receive under CT Cryosurgery or IRE surgery to control the local tumor
- interventionNames
- Procedure: Cryosurgery or IRE surgery
- type
- EXPERIMENTAL
- label
- Group B
- description
- In this group, the patients will receive multiple high-activity γδ T cell immunotherapies. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell)
- interventionNames
- Biological: γδ T cell
- type
- EXPERIMENTAL
- label
- Group C
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: Age: 18-75 Karnofsky performance status \>50 Diagnosis with Lung Cancer based on histology or the current accepted radiological measures Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ Will receive cryosurgery, IRE, gd T cells Life expectancy: Greater than 3 months Ability to understand the study protocol and a willingness to sign a written informed consent document Exclusion Criteria: Patients with other kinds of cancer History of coagulation disorders or anemia Patients with heart disease
References
Publications (0)
Data not yet available
No reference posted for this study.